 CEA and CAS for patients
with neurologic symptoms. However, the trial was
stopped after the recruitment of 1200 patients owing to
the futility of proving equivalence between the two treatments. The rate of death or ipsilateral stroke at 30 days
was 6.84% for CAS and 6.34% for CEA in for randomized
patients. However, the study was not powered appropriately and failed to show the noninferiority of